

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 August 2020 (06.08.2020)



(10) International Publication Number
WO 2020/160560 A2

(51) International Patent Classification:
C07K 16/30 (2006.01)

(21) International Application Number:
PCT/US2020/016459

(22) International Filing Date:
03 February 2020 (03.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/800,359 01 February 2019 (01.02.2019) US
62/891,925 26 August 2019 (26.08.2019) US

(71) Applicant: **NOVAROCK BIOTHERAPEUTICS, LTD.**
[US/US]; 801 South Princeton Corporate Center, Ewing
Township, NJ 08628 (US).

(72) Inventors: **LI, Han**; 1 Claire Dr, Newtown, PA 18940
(US). **LEI, Ming**; 20 Lockwood Dr, Princeton, NJ 08540
(US). **PEI, Yi**; 1836 Glenwold Dr, Paoli, PA 19301 (US).
HUANG, Haichun; 2425 Sueno Way, Fremont, CA 94539
(US).

(74) Agent: **WARREN, Lisa, M.**; Morse, Barnes-Brown &
Pendleton P.C., CityPoint, 480 Totten Pond Road, 4th Floor,
Waltham, MA 02451 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- without international search report and to be republished
upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOF




FIG. 3A

(57) Abstract: Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.



WO 2020/160560 A2